TTK and cancer: Although currently no drugs to treat cancer that target Mps1 catalytic activity have been approved for their use in the clinic, some Mps1 kinase inhibitors have been advanced to clinical trials, such as the compounds termed BAY 1217389 and BAY 1161909 [25,26].